+44 (0) 1793 575 050
service@jointoperations.co.uk

Viscosupplementation

Viscosupplementation is a safe and well established treatment which provides pain relief and increased mobility through the use of single or multiple Hyaluronic Acid injections.

Hyaluronic Acid or HA is a naturally occurring biocompatible molecule found throughout the body that is a vital component of healthy joints and tissue function. HA is naturally found in high concentrations in synovial fluid that bathes the knee and other joints. Synovial fluid reduces friction, helps lubricate and cushions articulating joints allowing the bones to move smoothly.

 

CINGAL® is a novel combination HA plus steroid single-injection treatment for the pain associated with osteoarthritis. CINGAL® combines the high molecular weight cross-linked hyaluronic acid (HA) formulation of MONOVISC® with a corticosteroid for additional short-term pain relief.

CINGAL® is indicated as a viscoelastic supplement or a replacement for synovial fluid in human joints. CINGAL® is well suited for rapid and long term relief of the symptoms of human joint dysfunctions such as osteoarthritis. The actions of CINGAL® are long term relief of symptoms by lubrication and mechanical support supplemented by short-term pain relief provided by triamcinolone hexacetonide (TH).

The product contains 22 mg/mL high molecular weight crosslinked hyaluronic acid produced from bacterial fermentation, 4.5 mg/mL triamcinolone hexacetonide.

 

MONOVISC is a sterile, non-pyrogenic, sodium hyaluronate solution, lightly cross-linked with a proprietary chemical cross-linker.

MONOVISC contains 22 mg/mL of lightly cross-linked sodium hyaluronate (NaHA) dissolved in phosphate-buffered saline at physiological osmolality. It is manufactured from ultra-pure, high molecular weight sodium hyaluronate produced by bacterial fermentation.

MONOVISC Cross-Linked Sodium Hyaluronate Injection is a single, intra-articular injection of cross-linked sodium hyaluronate designed to treat the symptoms of osteoarthritis. MONOVISC is indicated as a viscoelastic supplement or a replacement for synovial fluid in human joints. The actions of MONOVISC are lubrication and mechanical support.

 

ORTHOVISC is an ultra-pure, high molecular weight injectable hyaluronic acid (HA) viscosupplement used to treat the joint pain caused by osteoarthritis. It is comprised of highly purified sodium hyaluronate (NaHA) in physiologic saline, and it is both biocompatible and resorbable. ORTHOVISC is a non-animal sourced viscosupplement that may provide up to 6 months of efficacy with only 3 to 4 injections.

Viscosupplementation

Viscosupplementation is a safe and well established treatment which provides pain relief and increased mobility through the use of single or multiple Hyaluronic Acid injections.

Hyaluronic Acid or HA is a naturally occurring biocompatible molecule found throughout the body that is a vital component of healthy joints and tissue function. HA is naturally found in high concentrations in synovial fluid that bathes the knee and other joints. Synovial fluid reduces friction, helps lubricate and cushions articulating joints allowing the bones to move smoothly.

 

CINGAL® is a novel combination HA plus steroid single-injection treatment for the pain associated with osteoarthritis. CINGAL® combines the high molecular weight cross-linked hyaluronic acid (HA) formulation of MONOVISC® with a corticosteroid for additional short-term pain relief.

CINGAL® is indicated as a viscoelastic supplement or a replacement for synovial fluid in human joints. CINGAL® is well suited for rapid and long term relief of the symptoms of human joint dysfunctions such as osteoarthritis. The actions of CINGAL® are long term relief of symptoms by lubrication and mechanical support supplemented by short-term pain relief provided by triamcinolone hexacetonide (TH).

The product contains 22 mg/mL high molecular weight crosslinked hyaluronic acid produced from bacterial fermentation, 4.5 mg/mL triamcinolone hexacetonide.

 

MONOVISC is a sterile, non-pyrogenic, sodium hyaluronate solution, lightly cross-linked with a proprietary chemical cross-linker.

MONOVISC contains 22 mg/mL of lightly cross-linked sodium hyaluronate (NaHA) dissolved in phosphate-buffered saline at physiological osmolality. It is manufactured from ultra-pure, high molecular weight sodium hyaluronate produced by bacterial fermentation.

MONOVISC Cross-Linked Sodium Hyaluronate Injection is a single, intra-articular injection of cross-linked sodium hyaluronate designed to treat the symptoms of osteoarthritis. MONOVISC is indicated as a viscoelastic supplement or a replacement for synovial fluid in human joints. The actions of MONOVISC are lubrication and mechanical support.

 

ORTHOVISC is an ultra-pure, high molecular weight injectable hyaluronic acid (HA) viscosupplement used to treat the joint pain caused by osteoarthritis. It is comprised of highly purified sodium hyaluronate (NaHA) in physiologic saline, and it is both biocompatible and resorbable. ORTHOVISC is a non-animal sourced viscosupplement that may provide up to 6 months of efficacy with only 3 to 4 injections.